dc.contributor.author | Touret, F, et al. Unité des Virus Emergents, UVE: Aix Marseille Univ. | |
dc.date.accessioned | 2020-03-20T17:59:39Z | |
dc.date.available | 2020-03-20T17:59:39Z | |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0166354220301145 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/493 | |
dc.description.abstract | Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research. | en_US |
dc.subject | COVID-19 | |
dc.subject | Coronavirus | |
dc.subject | Infectious Diseases | |
dc.subject | SARS-CoV | |
dc.subject | Chloroquine | |
dc.subject | Hydroxychloroquine | |
dc.title | Of Chloroquine and COVID-19 | en_US |
eihealth.country | Others | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Research protocol information | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |